How Melanoma Resists PD-1 Blockade

Abstract

Researchers at the University of California, Los Angeles, have shed light on mechanisms by which melanoma cells become resistant to PD-1 blockade with pembrolizumab. One mechanism involves loss-of-function mutations in JAK1 or JAK2 that abolish interferon-γ signaling; the other involves a truncating mutation in B2M that results in defective antigen presentation.